Atypical Parkinsonism in the French West Indies: The Plant Toxin Annonacin as a Potential Etiological Factor

  • Annie Lannuzel
  • Patrick Pierre Michel
Part of the Contemporary Neuroscience book series (CNEURO)

This chapter describes the phenotypic and clinical features of an atypical parkinsonian syndrome endemic to the Caribbean island of Guadeloupe. The clinical entity was much more frequent than idiopathic Parkinson’s disease. It corresponded to a unique combination of levodopa-resistant parkinsonism, tremor, myoclonus, hallucinations, REM sleep behavior disorder and fronto-subcortical dementia. Epidemiological and experimental studies suggested that the neurological syndrome resulted from chronic intoxication by a mitochondrial complex I inhibitor, the plant toxin annonacin.


Progressive Supranuclear Palsy Progressive Supranuclear Palsy Atypical Parkinsonism Progressive Supranuclear Palsy Patient Atypical Parkinsonian Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Angibaud G, Gaultier C, Rascol O. Atypical parkinsonism and Annonaceae consumption in New Caledonia. Mov Disord 2004;19:603–604.PubMedCrossRefGoogle Scholar
  2. 2.
    Arnulf I, Merino-Andreu M, Bloch F, Konofal E, Vidailhet M, Cochen V, Derenne JP, Agid Y. REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep 2005; 28: 349–54PubMedGoogle Scholar
  3. 3.
    Caparros-Lefebvre D, Elbaz A and the Carribean Parkinsonism Study Group. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case control study. Lancet 1999; 354: 281–86.Google Scholar
  4. 4.
    Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, Brice A, Tolosa E, Delacourte A, Duyckaerts C. Guadeloupean Parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002; 125: 801–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Champy P, Höglinger GU, Féger J, Gleye C, Hocquemiller R, Laurens A, Guérineau V, Lapréote O, Medja F, Lombvs A, Michel PP, Lannuzel A, Hirsch EC, Ruberg M. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem 2004; 88: 63–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Champy P, Melot A, Guérineau Eng V, Gleye C, Fall D, Höglinger GU, Ruberg M, Lannuzel A, Laprévote O, Laurens A, Hocquemiller R. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe. Mov Disord 2005; 20: 1629–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaudhuri KR, Hu MTM, Brooks DJ. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the U. K. Mov Disord 2000; 15: 18–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889–909. Review.PubMedCrossRefGoogle Scholar
  9. 9.
    de Cock VC, Lannuzel A, Verhaeghe S, Roze E, Ruberg M, Derenne JP, Willer JC, Vidailhet M, Arnulf I. REM sleep behavior disorder in patients with Guadeloupean parkinsonism, a tauopathy. Sleep 2007; 30: 1026–32.PubMedGoogle Scholar
  10. 10.
    de Rick MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. European community concerted action on the epidemiology of PD. J Neurol Neurosurg Psychiatry 1997; 62: 10–15.CrossRefGoogle Scholar
  11. 11.
    Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J Neurol Sci 2007; 262:37–44.PubMedCrossRefGoogle Scholar
  12. 12.
    Escobar-Khondiker M, Höllerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, Höglinger GU. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 2007; 27: 7827–37.PubMedCrossRefGoogle Scholar
  13. 13.
    Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM and Scott WK. Pesticide exposure and risk of Parkinson's disease: A family-based case-control study. BMC Neurology 2008; 8:6PubMedGoogle Scholar
  14. 14.
    Höglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC. Chronic systemic inhibition of mitochondrial complex I induces a hypokinetic syndrome in rats with degeneration of multiple neuronal systems. J Neurochem 2003; 84:1–12.CrossRefGoogle Scholar
  15. 15.
    Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598–605.PubMedCrossRefGoogle Scholar
  16. 16.
    Lannuzel A, Michel PP, Caparros-Lefebvre D, Abaul J, Hocquemiller R, Ruberg M. Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe. Mov Disord 2002; 17: 84–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Lannuzel A, Michel PP, Höglinger GU, Champy P, Jousset A, Medja F, Lombé A, Darios F, Gleye C, Laurens A, Hocquemiller R, Hirsch EC, Ruberg M. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 2003; 121: 287–96.PubMedCrossRefGoogle Scholar
  18. 18.
    Lannuzel A, Höglinger GU, Verhaeghe S, Gire L, Belson S, Escobar-Khondiker M, Poullain P, Oertel WH, Hirsch EC, Dubois B, Ruberg M. Atypical parkinsonism in Guadeloupe: A common risk factor for two closely related phenotypes? Brain 2007; 130: 816–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop [Review]. Neurology 1996a; 47: 1–9.PubMedGoogle Scholar
  20. 20.
    Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study [Review]. J Neurol Neurosurg Psychiatry 1996b; 60: 615–20.PubMedCrossRefGoogle Scholar
  21. 21.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop [Review]. Neurology 1996; 47: 1113–24.PubMedGoogle Scholar
  22. 22.
    McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Work Group on Frontotemporal Dementia and Pick’s Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on frontotemporal dementia and Pick’s disease. Arch Neurol 2001; 58: 1803–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Menza MA, Cocchiola J, Golbe LI. Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics 1995; 36: 550–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Michel PP, Alvarez-Fischer D, Guerreiro S, Hild A, Hartmann A, Hirsch EC. Role of activity-dependent mechanisms in the control of dopaminergic neuron survival. J Neurochem 2007; 101: 289–97. Review.PubMedCrossRefGoogle Scholar
  25. 25.
    Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci 2007; 95:196–204.PubMedCrossRefGoogle Scholar
  26. 26.
    Righini A, Antonini A, De Notaris R, Bianchini E, Meucci N, Sacilotto G, Canesi M, De Gaspari D, Triulzi F, Pezzoli G. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. AJNR Am J Neuroradiol 2004; 25: 927–32.Google Scholar
  27. 27.
    Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247–58.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.INSERM, UMR_S 975, Neurology and Experimental TherapeuticsF-75013 ParisFrance
  2. 2.UPMC Univ Paris 06, UMR_S 975F-75005 ParisFrance
  3. 3.Department of NeurologyCentre Hospitalier UniversitaireF-97159 Pointe-à-Pitre

Personalised recommendations